22nd Century Group, Inc.

22nd Century Group, Inc. (NASDAQ: XXII) is a U.S.-based tobacco products company built around tobacco harm reduction and contract manufacturing. Its core differentiation is proprietary agricultural biotechnology that regulates nicotine biosynthesis in the tobacco plant, enabling reduced nicotine content (RNC) tobacco and cigarettes marketed under the VLN® brand. The company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette (December 2021), which supports its positioning in reduced-nicotine products. Alongside its own branded offerings, it operates a vertically integrated contract manufacturing operation (CMO) producing conventional cigarettes and branded filtered cigars for third parties, including export-oriented customers.

−63,0 %

42,1 %

−28,7 %

−27,9 %

2.42

1.83

— 22nd Century Group, Inc.
%
Contract manufacturing (CMO) cigarettes55% Manufacturing of conventional cigarettes for third-party customers, including export volume and large contracted accounts.
Contract manufacturing (CMO) filtered cigars20% Production of branded filtered cigars for customers under manufacturing contracts with repricing and mix shifts affecting volumes.
VLN® reduced nicotine cigarettes15% Company-branded reduced nicotine combustible cigarettes supported by FDA MRTP authorization and harm-reduction positioning.
Cigarillo distribution5% Distribution-driven cigarillo sales that can be influenced by distributor stocking and sell-through dynamics.
Research cigarettes and other5% Non-recurring or project-based research cigarette orders (e.g., Spectrum®) and other ancillary tobacco-related revenue.

22nd Century’s customer base spans both B2B manufacturing clients and end-market tobacco consumers via its own brands...

  • Contract manufacturing (CMO) cigarette customersprimary

    Buy manufactured conventional cigarettes under contracts; value reliable supply, pricing terms, and capacity, including export-oriented volume.

  • Contract manufacturing (CMO) filtered cigar customerssecondary

    Outsource production of branded filtered cigars; purchase decisions driven by unit economics, contract repricing, and product mix.

  • Adult smokers (VLN® end consumers via retail)secondary

    Purchase VLN® reduced nicotine cigarettes for nicotine reduction; demand depends on retail availability and harm-reduction positioning (MRTP).

  • Distributors (cigarillo channel)emerging

    Place stocking orders and distribute cigarillo products; ordering patterns can be lumpy due to inventory build and sell-through cycles.

  • Research/institutional customersemerging

    Buy research cigarettes for studies and testing; tends to be episodic (e.g., one-time Spectrum® order).

The company is headquartered in the United States and primarily serves U.S.-based customers across its contract...

  • •United States is the primary operating and customer market
  • •Export-linked sales occur via U.S. customers purchasing for export
  • •Vertical integration concentrates operational execution in owned facilities
  • •U.S. regulatory environment (FDA/MRTP) is central to VLN® positioning
  • •Export mix can change realized pricing and reported revenue per carton

The company’s strategy centers on tobacco harm reduction through commercialization of VLN® reduced nicotine cigarettes...

01
Expand CMO customer base and optimize contract economicsshort-term

CMO volumes are a key near-term revenue driver; pricing terms can materially affect reported revenue and margins.

02
Commercialize and build demand for VLN® reduced nicotine cigarettesmedium-term

VLN® is the differentiated harm-reduction offering supported by MRTP authorization and proprietary RNC technology.

03
Improve product mix and profitability through repricing and category focusmedium-term

Mix shifts and contract repricing can raise gross margin and reduce dependence on low-priced export volume.

A central company-specific risk is dependence on a small number of contract manufacturing customers, where contract...

critical

Liquidity and going-concern style funding risk

The company disclosed significant losses, negative operating cash flow, and an accumulated deficit, increasing dependence on financing.

Scope
Corporate-wide
Materiality
high
high

CMO contract economics and customer concentration risk

Revenue and margin are sensitive to renegotiated terms (e.g., stepped changes in consideration payable) and reliance on large CMO customers.

Scope
Contract manufacturing cigarettes and cigars
Materiality
high
medium

Intangible asset impairment risk (patents)

The company recorded impairment of patents, indicating valuation sensitivity to commercialization prospects and future cash flows.

Scope
Patents and technology assets
Materiality
medium
Revenue recognition for CMO contracts (including consideration payable)
Affects net revenue, gross profit, and comparability vs legacy contracts
Over-time revenue recognition and contract revenue accruals
Timing of revenue and receivables/contract assets
Impairment of patents and other intangibles
Operating expenses and asset carrying values

Century Therapeutics, Inc.

IPSC · Biological Products, (No Diagnostic Substances)

Sky Century Investment, Inc.

SKYI · Services-Management Services

VPR Brands, LP.

VPRB · Services-Prepackaged Software

Target Group Inc.

CBDY · Medicinal Chemicals & Botanical Products

Century Communities, Inc.

CCS · Operative Builders

Vincerx Pharma, Inc.

Pharmaceutical Preparations

: 11/08/2026